A preliminary trial of Russia’s Sputnik V COVID-19 vaccine suggests that a two-dose regimen of the vaccine offers 91.6% efficacy against symptomatic COVID-19, according to findings published on Tuesday (2 February). At the same time, the European Commission confirmed it does not rule out a deal for the vaccine.
The preliminary findings, published in The Lancet, are based on an analysis of Phase 3 trial data from nearly 20,000 participants, three-quarters of whom received the vaccine and one-quarter received a placebo.
It found that the vaccine induced an antibody and cellular immune response with data from 342 and 44 participants, respectively.
No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at the injection site and weakness or low energy.